SLC38A3 Drug Discovery Landscape & Assay Solutions

  • By admin
  • 18 Aug 2026
  • Comments

Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Reprogramming & Immuno-Oncology Development.

TarMart Solution Ecosystem & Related Targets

Comprehensive reagent toolkit for SLC38A3 (SNAT3) drug discovery. Select your modality below:

Component / Network Product Description Product Link
Antigen SLC38A3 ECL-Fc / Mutant Protein
High purity (>95%), Endotoxin <1EU/ug. Sequence Verified.		 View SLC38A3 Products
Gene Delivery SLC38A3 Lentivirus Premade Particles
Full-length ORF, Puromycin selection, >1×10⁸ TU/mL, HEK293T packaged. Sequence Verified. Also available: SLC38A3 Promise-ORF for transfection (Codon-optimized, C-terminal FLAG tag).		 View SLC38A3 Products
ORF Clone SLC38A3 Promise-ORF
Codon-optimized for mammalian expression, C-terminal FLAG tag, Ready for transfection.		 View SLC38A3 Products
Benchmark Ab Anti-SLC38A3 (Discovery Benchmark)
Recombinant positive control for target binding validation.		 View SLC38A3 Products
Validator SLC38A3 siRNA Set
For knockdown verification and specificity screening.		 View SLC38A3 Products
Compensatory Pathway SLC1A5 (ASCT2) Lentivirus & Protein
Primary glutamine transporter; counter-screening essential for specificity.		 View SLC1A5 Products
Synergistic Target SLC7A5 (LAT1) Lentivirus
L-type amino acid transporter 1; coordinates with SLC38A3 in mTOR activation.		 View SLC7A5 Products
Downstream Enzyme GLS Recombinant Protein
Glutaminase, kidney-type (KGA); catalytic target downstream of glutamine import.		 View GLS Products
Metabolic Stress Partner SLC7A11 (xCT) Lentivirus
Cystine/glutamate antiporter; complementary glutamine pathway component.		 View SLC7A11 Products
Critical Assay Challenge The TarMart Advantage (Technical Spec)
Complex Membrane Protein Conformation (11-TM domain) Lentivirus-delivered full-length SLC38A3 with native glycosylation pattern; stable integration ensures physiological membrane orientation. Premade lentivirus particles enable >95% transduction efficiency.
Extracellular Loop (ECL) Targeting Rational design of ECL-specific fusion proteins, Sequence Verified, HEK293 Expressed (Native Glycosylation).
Compensatory Pathway Cross-reactivity (vs. SLC1A5/SLC7A5) Ortholog-specific ORF clones (Human/Mouse/Cyno) strictly sequence-verified for selectivity profiling.
High-throughput Glutamine Uptake Quantification High-titer lentivirus enables uniform stable cell lines for [³H]-glutamine or fluorescent analog uptake assays.
Lack of Controls Discovery Benchmark Antibodies included for assay standardization.
False Positives in Screening Validated siRNA included for strict biological specificity checks.
Endogenous Expression Background Interference Empty vector lentivirus controls and SLC38A3-targeting siRNA sets included for normalization and specificity confirmation.

Live SLC38A3 R&D Tracker

Market data changes daily. Access the latest global pipeline status directly:

Global Clinical Landscape & Future Outlook

The race for SLC38A3 (SNAT3) therapeutics is intensifying as researchers uncover its critical role in glutamine homeostasis and ammonia detoxification. While traditionally targeted by small molecule inhibitors for metabolic disorders, the oncology space is recognizing SLC38A3 as a key driver of tumor glutamine addiction. Moreover, SLC38A3 emerges as a critical bypass mechanism for glutamine acquisition in tumors resistant to SLC1A5 (ASCT2) inhibition. The current R&D focus centers on small molecule inhibitors that selectively block the sodium-binding pocket without disrupting related SLC38 family members (SLC38A1/A2). As first-generation metabolic inhibitors face resistance challenges in Phase I/II trials, the industry is pivoting toward combination strategies targeting SLC38A3 to prevent compensatory pathway activation and achieve complete metabolic blockade. Additionally, variants in SLC38A3 (e.g., those reported in UniProt VAR_087292–VAR_087294) are associated with developmental and epileptic encephalopathy 102 (DEE102), though the clinical significance remains uncertain; this adds a potential link to neurological indications beyond oncology and metabolism. As first-generation discovery programs evolve, the next wave of R&D is targeting selective extracellular loop (ECL) binding and synergistic combinations with other metabolic inhibitors.

Competitive Modality & Indication Snapshot

Connect market trends to assay needs. The table below summarizes key modalities, representative players, indications, and the critical assay needs addressed by TarMart reagents.

Modality Representative Players Key Indications Critical Assay Need (Why TarMart?)
Small Molecule Inhibitor Emerging Biotechs, Academic Consortia, Discovery Phase Biotechs Solid Tumors, Metabolic Diseases, Hepatocellular Carcinoma Cell-based uptake assays using Lentivirus-stable lines expressing full-length SLC38A3.
Monoclonal Antibody Academic / Early Pharma Cancer Metabolism ECL Binding Assay (Need high-purity ECL-Fc fragments).
siRNA / ASO Metabolic-Focused Biotechs, Preclinical Innovators Liver Metastases, Immune Evasion, Liver/Kidney Disorders Knockdown validation reagents (siRNA sets) with standardized negative controls.
Combination Therapy (Metabolic + I/O) Immuno-Oncology Leaders PD-1 Resistant Tumors Dual-target cell lines (SLC38A3 + SLC7A5) for synergy screening.